Article via https://www.nih.gov on 15 May 2023
Clinical trial of mRNA universal influenza vaccine candidate begins. NIAIDA clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina.
The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine.
This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines.
Although annual seasonal flu vaccines are valuable tools in controlling the spread and severity of influenza, they do not provide immunity against every flu strain.
It is the first investigational universal flu vaccine candidate to be tested by the CIVICs program, and was manufactured at the facilities of the Duke Human Vaccine Institute (DHVI), which is a part of the CIVICs program.